奥美拉唑伊托必利和铝镁加联合治疗反流性食管炎疗效观察.docVIP

奥美拉唑伊托必利和铝镁加联合治疗反流性食管炎疗效观察 　　[摘要] 目的 探讨奥美拉唑、伊托必利和铝镁加联合治疗反流性食管炎的临床疗效。方法 将53例反流性食管炎患者随机分为对照组(26例)和观察组(27例),对照组予口服奥美拉唑、伊托必利等综合治疗,观察组在对照组综合治疗的基础上加服铝镁加混悬液15mL,3次/d,于治疗8周后复查胃镜,观察镜下治愈率。结果 对照组内镜下治愈率为65.4%,观察组内镜下治愈率为92.6%,两组比较有统计学意义(P0.05)。结论 在口服奥美拉唑、伊托必利等综合治疗的基础上,加服铝镁加能提高反流性食管炎的治疗效果。 　　[关键词] 反流性食管炎; 胃食管反流病; 奥美拉唑; 伊托必利; 铝镁加 　　[中图分类号] R571 [文献标识码] A [文章编号] 1673-9701(2010)03-155-02 　　 　　Combination of Omeprazole,Itopride and Almagate for Reflux Esophagitis 　　SHI Rongjie YANG Liwei WU Zesheng HE Fang 　　NO.2 Department of Internal Medicine,the Affiliated Hospital of Dali University,Dali 671000,China 　　 　　[Abstract] ObjectiveTo evaluate the effects of Omeprazole combined with Itopride and Almagate in the treatment of reflux esophagitis. MethodsFifty-three cases of reflux exsophagitis were randomly divided into two groups:observation group (n=27)and control group(n=26). Both groups were given Omeprazole and Itopride,and Almagate suspension was added to the observation group(n=27)15ml(3 times a day),and at the end of 8-week treatment,the curative rate was rechecked by endoscope. ResultsThe curative rate under endoscope was 65.4% in the control group and 92.6% in the observation group,respectively,and the difference between the two groups was significant(P0.05). ConclusionOmeprazole combined with Itopride and Almagate can effectively improve the curative effect in the treatment of reflux esophagitis. 　　[Key words]Reflux esophagitis; Gastroesophageal reflux disease; Omeprazole; Itopride; Almagate 　　 　　反流性食管炎(reflux esophagitis,RE)是指因食管胃连接部防反流机构障碍而导致胃或肠内容物反流入食管,从而引起食管炎症,也有人称之为胃食管反流病(gastroesophageal reflux disease,GERD)[1]。自2006年1月起,笔者对RE患者在口服奥美拉唑、伊托必利等综合治疗的基础上加服铝镁加混悬液,取得较好疗效,现报道如下。 　　1 资料与方法 　　1.1 一般资料 　　选择RE患者共53例,其中男35例,女18例,平均年龄(45.8±18.6)岁。将53例患者随机分为对照组和观察组,两组在临床表现、内镜检查及分级等方面比较差异均无统计学意义(P0.05),具有可比性,见表1。 　　1.2 入选标准及排除标准 　　入选标准:年龄16～68岁,性别不限,所有患者均经同一医师行胃镜检查确诊为RE,按洛杉矶分级标准分为4级[2],其中A级30例,B级14例,C级6例,D级3例。排除标准:有严重心、脑、肺、肾及肝脏疾病者和两周内服用过抑酸剂及胃肠动力药物者。 　　1.3 治疗方法 　　对照组予口服